Oguchi disease: Difference between revisions
CSV import |
CSV import |
||
| Line 1: | Line 1: | ||
[[File:Autosomal_recessive_-_en.svg| | {{SI}} | ||
{{Infobox medical condition | |||
| name = Oguchi disease | |||
| image = [[File:Autosomal_recessive_-_en.svg|200px]] | |||
| caption = Oguchi disease is inherited in an [[autosomal recessive]] pattern. | |||
| synonyms = [[Congenital stationary night blindness]] type 2 | |||
| field = [[Ophthalmology]] | |||
| symptoms = [[Night blindness]], [[abnormal fundus reflex]] | |||
| onset = [[Childhood]] | |||
| duration = [[Lifelong]] | |||
| causes = Mutations in the [[SAG (gene)|SAG]] or [[GRK1]] genes | |||
| risks = [[Consanguinity]] | |||
| diagnosis = [[Electroretinography]], [[genetic testing]] | |||
| differential = [[Retinitis pigmentosa]], [[fundus albipunctatus]] | |||
| treatment = No specific treatment; [[low vision aids]] | |||
| prognosis = Stable vision with no progression | |||
| frequency = Rare | |||
| deaths = None directly attributable | |||
}} | |||
'''Oguchi disease''' is a rare, autosomal recessive [[congenital]] [[stationary night blindness]] (CSNB) disorder characterized by a unique golden or grayish discoloration of the [[retina]] that reverses after prolonged dark adaptation. This condition is named after the Japanese ophthalmologist Chuta Oguchi, who first described it in 1907. | |||
== Clinical Features == | == Clinical Features == | ||
Patients with Oguchi disease typically present with [[night blindness]] (nyctalopia) from an early age. Despite the significant difficulty in seeing in low-light conditions, their [[daytime vision]] remains relatively normal. The hallmark of Oguchi disease is the Mizuo-Nakamura phenomenon, where the abnormal golden or grayish discoloration of the retina disappears after several hours of darkness, revealing a normal-appearing retina. | Patients with Oguchi disease typically present with [[night blindness]] (nyctalopia) from an early age. Despite the significant difficulty in seeing in low-light conditions, their [[daytime vision]] remains relatively normal. The hallmark of Oguchi disease is the Mizuo-Nakamura phenomenon, where the abnormal golden or grayish discoloration of the retina disappears after several hours of darkness, revealing a normal-appearing retina. | ||
== Pathophysiology == | == Pathophysiology == | ||
Oguchi disease is caused by mutations in genes involved in the phototransduction pathway in the [[retina]]. The two primary genes associated with this condition are [[SAG]] (S-arrestin) and [[GRK1]] (G protein-coupled receptor kinase 1). Mutations in these genes disrupt the normal function of rod photoreceptors, leading to impaired dark adaptation and night blindness. | Oguchi disease is caused by mutations in genes involved in the phototransduction pathway in the [[retina]]. The two primary genes associated with this condition are [[SAG]] (S-arrestin) and [[GRK1]] (G protein-coupled receptor kinase 1). Mutations in these genes disrupt the normal function of rod photoreceptors, leading to impaired dark adaptation and night blindness. | ||
== Diagnosis == | == Diagnosis == | ||
The diagnosis of Oguchi disease is primarily clinical, based on the characteristic retinal appearance and the Mizuo-Nakamura phenomenon. [[Electroretinography]] (ERG) can be used to confirm the diagnosis, showing a typical pattern of reduced rod function with relatively preserved cone function. Genetic testing can identify mutations in the SAG or GRK1 genes, providing a definitive diagnosis. | The diagnosis of Oguchi disease is primarily clinical, based on the characteristic retinal appearance and the Mizuo-Nakamura phenomenon. [[Electroretinography]] (ERG) can be used to confirm the diagnosis, showing a typical pattern of reduced rod function with relatively preserved cone function. Genetic testing can identify mutations in the SAG or GRK1 genes, providing a definitive diagnosis. | ||
== Treatment == | == Treatment == | ||
There is currently no cure for Oguchi disease. Management focuses on coping strategies for night blindness, such as using bright lighting and avoiding activities in low-light conditions. Genetic counseling may be beneficial for affected individuals and their families. | There is currently no cure for Oguchi disease. Management focuses on coping strategies for night blindness, such as using bright lighting and avoiding activities in low-light conditions. Genetic counseling may be beneficial for affected individuals and their families. | ||
== Epidemiology == | == Epidemiology == | ||
Oguchi disease is extremely rare, with most cases reported in Japan. However, it has been identified in various populations worldwide. The exact prevalence is unknown due to its rarity and the potential for misdiagnosis as other forms of night blindness. | Oguchi disease is extremely rare, with most cases reported in Japan. However, it has been identified in various populations worldwide. The exact prevalence is unknown due to its rarity and the potential for misdiagnosis as other forms of night blindness. | ||
== See Also == | == See Also == | ||
* [[Night blindness]] | * [[Night blindness]] | ||
| Line 22: | Line 35: | ||
* [[Phototransduction]] | * [[Phototransduction]] | ||
* [[Electroretinography]] | * [[Electroretinography]] | ||
== References == | == References == | ||
{{Reflist}} | {{Reflist}} | ||
== External Links == | == External Links == | ||
{{Commons category|Oguchi disease}} | {{Commons category|Oguchi disease}} | ||
[[Category:Genetic disorders]] | [[Category:Genetic disorders]] | ||
[[Category:Ophthalmology]] | [[Category:Ophthalmology]] | ||
[[Category:Autosomal recessive disorders]] | [[Category:Autosomal recessive disorders]] | ||
[[Category:Rare diseases]] | [[Category:Rare diseases]] | ||
{{medicine-stub}} | {{medicine-stub}} | ||
Latest revision as of 06:11, 8 April 2025
Editor-In-Chief: Prab R Tumpati, MD
Obesity, Sleep & Internal medicine
Founder, WikiMD Wellnesspedia &
W8MD's medical weight loss NYC, sleep center NYC
Philadelphia medical weight loss and Philadelphia sleep clinics
| Oguchi disease | |
|---|---|
| |
| Synonyms | Congenital stationary night blindness type 2 |
| Pronounce | N/A |
| Specialty | N/A |
| Symptoms | Night blindness, abnormal fundus reflex |
| Complications | N/A |
| Onset | Childhood |
| Duration | Lifelong |
| Types | N/A |
| Causes | Mutations in the SAG or GRK1 genes |
| Risks | Consanguinity |
| Diagnosis | Electroretinography, genetic testing |
| Differential diagnosis | Retinitis pigmentosa, fundus albipunctatus |
| Prevention | N/A |
| Treatment | No specific treatment; low vision aids |
| Medication | N/A |
| Prognosis | Stable vision with no progression |
| Frequency | Rare |
| Deaths | None directly attributable |
Oguchi disease is a rare, autosomal recessive congenital stationary night blindness (CSNB) disorder characterized by a unique golden or grayish discoloration of the retina that reverses after prolonged dark adaptation. This condition is named after the Japanese ophthalmologist Chuta Oguchi, who first described it in 1907.
Clinical Features[edit]
Patients with Oguchi disease typically present with night blindness (nyctalopia) from an early age. Despite the significant difficulty in seeing in low-light conditions, their daytime vision remains relatively normal. The hallmark of Oguchi disease is the Mizuo-Nakamura phenomenon, where the abnormal golden or grayish discoloration of the retina disappears after several hours of darkness, revealing a normal-appearing retina.
Pathophysiology[edit]
Oguchi disease is caused by mutations in genes involved in the phototransduction pathway in the retina. The two primary genes associated with this condition are SAG (S-arrestin) and GRK1 (G protein-coupled receptor kinase 1). Mutations in these genes disrupt the normal function of rod photoreceptors, leading to impaired dark adaptation and night blindness.
Diagnosis[edit]
The diagnosis of Oguchi disease is primarily clinical, based on the characteristic retinal appearance and the Mizuo-Nakamura phenomenon. Electroretinography (ERG) can be used to confirm the diagnosis, showing a typical pattern of reduced rod function with relatively preserved cone function. Genetic testing can identify mutations in the SAG or GRK1 genes, providing a definitive diagnosis.
Treatment[edit]
There is currently no cure for Oguchi disease. Management focuses on coping strategies for night blindness, such as using bright lighting and avoiding activities in low-light conditions. Genetic counseling may be beneficial for affected individuals and their families.
Epidemiology[edit]
Oguchi disease is extremely rare, with most cases reported in Japan. However, it has been identified in various populations worldwide. The exact prevalence is unknown due to its rarity and the potential for misdiagnosis as other forms of night blindness.
See Also[edit]
References[edit]
<references group="" responsive="1"></references>
External Links[edit]
This article is a medical stub. You can help WikiMD by expanding it!
